Bristol-Myers Squibb Co
BMY
Company Profile
Business description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
34,100
Bristol-Myers Squibb Co News & Analysis
stocks
10 cheap wide-moat US stocks for 2025
Undervalued high-quality names from the Morningstar Wide Moat Focus Index are attractive stocks to buy for long-term investors.
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,076.60 | 25.40 | -0.28% |
CAC 40 | 7,743.00 | 33.68 | 0.44% |
DAX 40 | 24,162.86 | 29.64 | -0.12% |
Dow JONES (US) | 44,175.61 | 206.97 | 0.47% |
FTSE 100 | 9,095.73 | 5.04 | -0.06% |
HKSE | 24,858.82 | 222.81 | -0.89% |
NASDAQ | 21,450.02 | 207.32 | 0.98% |
Nikkei 225 | 41,820.48 | 761.33 | 1.85% |
NZX 50 Index | 12,844.63 | 42.47 | -0.33% |
S&P 500 | 6,389.45 | 49.45 | 0.78% |
S&P/ASX 200 | 8,807.10 | 24.30 | -0.28% |
SSE Composite Index | 3,635.13 | 4.54 | -0.12% |